About US
Contact us
-
Regeneron loses bid to scrap infringement lawsuit linked to COVID antibody cocktailPfizer and BioNTech recently emerged from a lawsuit unscathed after Allele Biotechnology and Pharmaceuticals cried patent infringement against a trio of pandemic juggernauts. For Regeneron, however,2022/3/9
-
Amgen, NHS strike deal to expand Lumykras access in UK as watchdog weighs its meritsWhile England’s drug-price watchdog continues to assess the value of Amgen’s lung cancer drug Lumykras, the company and the National Health Service havestrucka deal to make the groundbreaking treatme2022/3/7
-
Billionaire Sackler family enters $6B opioid deal with support from holdout statesWhen OxyContin maker Purdue Pharma and its founding family inked a $4.3 billion opioid settlement back in September 2021, the judge overseeing the casecalledit a "bitter result." Now, thanks to an ap2022/3/7
-
Eli Lilly's Medicaid rebate payments under fire as whistleblower lawsuit heads to trialEli Lilly is headed to trial over claims it skimped on Medicaid rebate payments. U.S. District Judge Harry Leinenweber has shot down Lilly’s motion to end a 2014 whistleblower lawsuit, concludi2022/3/2
-
With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?Bayer is gradually shifting its pharma focus to a group of new blockbuster candidates and novel platforms. But before those drugs realize their potential, eye med Eylea and blood thinner Xarelto rema2022/3/2
-
Gilead's HIV prospect lenacapavir hits FDA approval snag amid vial compatibility concernsAfter a quality glitchscuppered multiple trials of an investigational HIV drug late last year, Gilead Sciences vowed to sort out the problem swiftly. Now, the drug also faces a hurdle on its path to2022/2/28
-
FibroGen’s roxadustat safety mess draws SEC scrutiny as AstraZeneca-partnered anemia drug remains in limboFibroGen and partner AstraZeneca have yet to figure out an FDA path for their once-rejected anemia drug roxadustat. And now, another regulator is piling into the mess. FibroGen received a subpo2022/2/28
-
Johnson & Johnson, Moderna set to face shareholder votes on vaccine pricing strategy, manufacturing tech sharingThroughout the global push to produce COVID-19 vaccines, pharma companies have frequently come under fire for unequal access to their shots. Oxfam, in a bid to force better access, has scored a pair2022/2/24
-
AbbVie advances major depressive disorder ambitions for Vraylar with hopes for $4B-plus in salesAbbVie’s Allergan-acquired antipsychotic medicine Vraylar is alreadygoing gangbusters in its twoapproved indications. An expansion into tough-to-treat depression, meanwhile, would only build on the m2022/2/24
-
Moderna taps Thermo Fisher for 15-year mRNA production pact for COVID vaccines and moreIn the third year of the pandemic, mRNA specialist Moderna is marshaling one of its tried-and-true manufacturing partners to lock up production of its COVID shot for years to come. Modern2022/2/22